Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells (Q39548383)

13 September 2017

title

Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells (English)

1 reference

13 September 2017

1 reference

Koji Hoshino

1

1 reference

13 September 2017

Hitoshi Ishiguro

2

1 reference

13 September 2017

Jun-Ichi Teranishi

3

1 reference

13 September 2017

Shin-Ichiro Yoshida

4

1 reference

13 September 2017

Satoshi Umemura

5

1 reference

13 September 2017

Yoshinobu Kubota

6

1 reference

13 September 2017

Hiroji Uemura

7

1 reference

13 September 2017

publication date

28 December 2010

1 reference

13 September 2017

1 reference

13 September 2017

volume

71

1 reference

13 September 2017

issue

9

1 reference

13 September 2017

page(s)

964-975

1 reference

13 September 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Androgen deprivation therapy for prostate cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

IL-1 is required for tumor invasiveness and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Interaction of IGF signaling and the androgen receptor in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Renin-angiotensin system is an important factor in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Regulation of cell proliferation and growth by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

The renin-angiotensin system and vascular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Transcription of the prorenin gene in normal and diseased breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Tissue-specific changes of type 1 angiotensin II receptor and angiotensin-converting enzyme mRNA in angiotensinogen gene-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Levels of angiotensin and molecular biology of the tissue renin angiotensin systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

The recovery of some components of the renin angiotensin system in the rat pancreas after chronic exposure to hypoxic condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

PPAR(gamma) and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Interleukin-6 regulation of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21312

21 January 2018

Identifiers

DOI

10.1002/PROS.21312

1 reference

13 September 2017

1 reference